Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma
Status:
Terminated
Trial end date:
2019-11-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if study treatment with atezolizumab and PEGPH20
given before and after surgery, followed by chemotherapy is safe and if it can further
increase the immune response against the tumor rather than increase the chance of cure.